Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lapatinib in the Treatment of Ductal Carcinoma in Situ of the Breast.

Next Previous
Search
Trial Profile

Lapatinib in the Treatment of Ductal Carcinoma in Situ of the Breast.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Breast cancer; Ductal carcinoma
  • Focus Therapeutic Use

Most Recent Events

  • 01 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
  • 01 Sep 2010 Additional lead trial investigator (Sunil Badve) identified as reported by ClinicalTrials.gov.
  • 01 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top